Biomarker-Driven Lung Cancer

Liza C. Villaruz, MD, discusses what research in the KRAS G12C-mutated non–small cell lung cancer space has appeared to be most promising in recent years.

Progression-free survival data from the phase 3 TROPION-Lung01 trial showed that datopotamab deruxtecan as treatment of metastatic non–small cell lung cancer crossed the threshold for statistical significance.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ticiana Leal, MD, discussed the use of sotorasib and adagrasib in patients with KRAS G12C mutations in non–small cell lung cancer.

Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, D. Ross Camidge, MD, PhD, discussed dosing and toxicity concerns with the KRAS inhibitors adagrasib and sotorasib.

Joshua K. Sabari, MD, discusses LY3537982 for patients with KRAS G12C-mutant advanced solid tumors.

Individual data from 2 studies evaluating rezivertinib in patients with advanced non–small cell lung cancer harboring an EGFR T790M mutation and CNS metastases displayed encouraging efficacy and safety findings.

In most key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer, sotorasib continued to demonstrate consistent benefit vs docetaxel.

In an interview with Targeted Oncology, Liza C. Villaruz, MD, discussed important new therapies for biomarker-driven NSCLC, and novel biomarkers that may bring new treatments in the near future.

Results from TRIDENT-1 are supporting a new drug application for repotrectinib, a potential treatment for ROS1-positive advanced non–small cell lung cancer.

Liza C. Villaruz, MD, discusses the latest areas of growth in the non–small cell lung cancer space.

Looking at real-world data, researchers identified a large increase of biomarker testing for patients with early-stage non–small cell lung cancer, which indicates a continuing trend toward personalized treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Corey J. Langer, MD, discussed the EMPOWER Lung-3 and POSEIDON trials of immunotherapy options in patients with non–small cell lung cancer.

Updated results from the phase 1 study of the bioavailable KRAS G12C inhibitor IBI351 showed that monotherapy was tolerable with promising activity in patients with advanced non–small cell lung cancer whose tumor harbored the KRAS G12C mutation.

With 1.5 years of follow-up, the confirmed objective response rate was 92.5% among patients who were ROS1 tyrosine kinase inhibitor-naïve and 52.6% in crizotinib-pretreated patients in the phase 2 TRUST-I trial.

A Tennessee Oncology location in Nashville was the first to dose the novel c-MET antibody-drug conjugate, MYTX-011, as part of the phase 1 KisMET-01 clinical trial.

Patients with PD-L1-positive non-small cell lung cancer that has metastasized to the brain did better with cemiplimab plus chemotherapy than with investigator's choice of chemotherapy.

Results from the phase 2 PHAROS trial of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non–small cell lung cancer has led the FDA to accept supplemental new drug applications for the agents. Further data will be presented at an upcoming medical meeting.

Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.

New results from the phase 2 APPLE trial shows how the use of osimertinib in the upfront setting compares with combination therapy in patients with EGFR-positive non–small cell lung cancer.

Looking at the results of study assessing performing blood-based host immune classifier proteomic testing in patients with non–small cell lung cancer shows the potential for predicting the success of immunotherapy based on a patient’s biomarkers.

A case report published in The Journal of the National Comprehensive Cancer Center highlights the importance of being mindful of unusual adverse events associated with BRAF/MEK inhibition for patients with BRAF-mutated non–small cell lung cancer.

Nicholas J. Robert, MD, discusses the poster on the MYLUNG Consortium that he presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Benjamin Philip Levy, MD, discussed systemic therapies for patients with ALK-rearranged metastatic non–small cell lung cancer and data from recent trials in this space.